1059182-77-2

Upstream product

• 32857-62-8 4-Trifluoromethylphenylacetic acid 
• 6315-89-5 3,4-dimethoxyaniline 

Downstream Products

• 1059182-78-3 (3,4-dimethoxy-phenyl)-[2-(4-trifluoromethyl-phenyl)-ethyl]-amine 
• 1059182-79-4 N-(3,4-dimethoxyphenyl)-2-phenyl-N-[2-(4-trifluoromethylphenyl)ethyl]malonamic acid benzyl ester 
• 1059182-75-0 N-(3,4-dimethoxyphenyl)-2,N',N'-trimethyl-2-phenyl-N-[2-(4-trifluoromethylphenyl)ethyl]malonamide 
• 1059182-10-3 N-(3,4-dimethoxyphenyl)-N'-methyl-2-phenyl-N-[2-(4-trifluoromethylphenyl)ethyl]malonamide 
• 1059182-80-7 N-(3,4-dimethoxyphenyl)-2-phenyl-N-[2-(4-trifluoromethylphenyl)ethyl]malonamic acid 

Relevant academic research and scientific papers

MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

The present invention relates to compounds of formulawherein Ar, R1, R2, R3, R4, R5, n, o, and p are as defined herein or to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. The compounds of formula I can be used for the treatment of sleep disorders, such as sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder or sleep disorders associated with neurological diseases.

MALONAMIDES AS OREXIN ANTAGONISTS

The present invention relates to compounds of formula wherein Ar1 and Ar2 are independently from each other unsubstituted or substituted aryl or heteroaryl; R1/R2 are independently from each other hydrogen, lower alkyl, lower alkyl substituted by halogen, -(CH2)o-O-lower alkyl, -(CH2)o-N-(lower alkyl)2, (CH2)p-cycloalkyl, (CH2)p-heterocycloalkyl, (CH2)p-aryl, (CH2)p-heteroaryl, which rings may be substituted by R, or R1 and R2 may form together with the N-atom to which they are attached a heterocyclic ring, optionally with further ring-heteroatoms selected from N, O or S, which ring may be substituted by R; R is halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy or lower alkoxy substituted by halogen; R3 is hydrogen or lower alkyl; n is O, 1, 2, 3 or 4; o is 1, 2 or 3; P is 0, 1 or 2; or to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. It has been found that the compounds of formula I are orexin receptor antagonists and the related compounds may be useful in the treatment of disorders, in which orexin pathways are involved like sleep disorders.